Altered relationship between body fat and plasma adiponectin in end-stage renal disease.
暂无分享,去创建一个
S. Fukumoto | H. Koyama | M. Emoto | T. Tabata | T. Shoji | Y. Nishizawa | E. Ishimura | T. Miki | E. Kimoto | K. Shinohara | H. Tahara | S. Hatsuda | Y. Nishizawà | Eiji Kimoto | Sawako Hatsuda
[1] T. Shoji,et al. Molecular forms of adiponectin in uraemic plasma. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] C. Yen,et al. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] K. Kalantar-Zadeh,et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. , 2003, Kidney international.
[4] M. Matsuda,et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.
[5] S. Kihara,et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[6] M. Emoto,et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.
[7] T. Tai,et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. , 2001, The Journal of clinical endocrinology and metabolism.
[8] T. Funahashi,et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. , 2001, Diabetes.
[9] T. Funahashi,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .
[10] S. Kihara,et al. Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.
[11] T. Shoji,et al. Additive impacts of diabetes and renal failure on carotid atherosclerosis. , 2000, Atherosclerosis.
[12] P. Stenvinkel,et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] T Nakamura,et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[14] T Nakamura,et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.
[15] T. Funahashi,et al. Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines · Adipocyte‐derived Bioactive Substances , 1999, Annals of the New York Academy of Sciences.
[16] T Nakamura,et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.
[17] T. Shoji,et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.
[18] R. Strawderman,et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] T. Shoji,et al. Plasma leptin level and its relationship with body composition in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] Y. Kubota,et al. Serum levels of total and free testosterone in men undergoing hemodialysis. , 1998, Archives of andrology.
[21] T. Shoji,et al. Renal function and insulin resistance as determinants of plasma leptin levels in patients with NIDDM , 1997, Diabetologia.
[22] S. Yamashita,et al. Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.
[23] T. Funahashi,et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.
[24] T. Shoji,et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. , 1995, Kidney international.
[25] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.
[26] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[27] P. Degoulet,et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. , 1982, Nephron.
[28] B. Scribner,et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.